✦ LIBER ✦

90Y-ibritumomab tiuxetan: Rationale for patient selection in the treatment of indolent non-Hodgkin’s lymphoma

✍ Scribed by Antonio J. Grillo-López

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of 90Y-ibritumomab tiuxetan in non-H

✍ Robert Marcus 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Efficacy and safety of 90Y ibritumomab t

✍ Thomas E Witzig 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 167 KB

Radioisotopic Localization of90Yttrium–I

✍ S. A. Jacobs; A. M. Harrison; S. H. Swerdlow; K. A. Foon; N. Avril; N. Vidnovic; 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 589 KB

Safety and Efficacy of Yttrium-90 Ibritu

✍ Emmanouilides, Christos; Witzig, Thomas E.; Wiseman, Gregory A.; Gordon, Leo I.; 📂 Article 📅 2007 🏛 Mary Ann Liebert 🌐 English ⚖ 149 KB

Factors Associated with Toxicity and Res

✍ Borghaei, Hossein; Wallace, Stephen G.; Schilder, Russell J. 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 113 KB

Current status and future perspectives f

✍ Gisselbrecht, C; Bethge, W; Duarte, R F; Gianni, A M; Glass, B; Haioun, C; Marti 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 223 KB